renca tumor cells  (ATCC)

Journal: Molecular Cancer Therapeutics

Article Title: Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models

doi: 10.1158/1535-7163.MCT-25-0108

Figure Lengend Snippet: Tumor-targeted ncSTING ADCs drive antitumor activity across multiple tumor models with multiple tumor antigens. Mean tumor volume over time of ( A ) human CD228-LL2 tumor–bearing C57BL/6 mice, ( B ) murine B7-H4-EMT6 tumor–bearing C57BL/6 mice, ( C ) murine B7-H4-Renca tumor–bearing Balb/c mice, and ( D ) murine IB6-CT26 tumor–bearing Balb/c mice following treatment with three weekly intraperitoneal doses (arrows) of the indicated ADCs. Data in each panel represent a single in vivo experiment. Following a one-way ANOVA test, a Tukey post hoc multiple comparisons test was used to compare each treatment group: ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05. Error bars depict SD.

Article Snippet: Renca tumor cells (ATCC, #CRL-2947, RRID:CVCL_2174; purchased in 2004) were cultured in RPMI 1640 medium (ATCC) with 10% heat-inactivated FBS, MEM nonessential amino acids (0.1 mmol/L), sodium pyruvate (1 mmol/L), and L-glutamine (2 mmol/L) and implanted subcutaneously (2 × 10 6 cells in 200 μL 25% Matrigel in RPMI 1640) into Balb/c female mice (RRID:IMSR_ENV:HSD-047).

Techniques: Activity Assay, In Vivo

Journal: Molecular Cancer Therapeutics

Article Title: Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models

doi: 10.1158/1535-7163.MCT-25-0108

Figure Lengend Snippet: Tumor-targeted STING agonist delivery via an ADC minimizes systemic cytokine induction compared with systemic delivery of the released payload. A and C, Mean tumor volume over time of Renca tumor–bearing Balb/c mice following treatment with three weekly intravenous ( A ) or intraperitoneal ( C ) doses (arrows) of the indicated ADCs or released payload. B and D, Quantification of IL-6 in the plasma 3, 6, and 24 hours following treatment as in A and C . Data in each panel represent a single in vivo experiment. Following a one-way ANOVA test, a Tukey post hoc multiple comparisons test was used to compare AUC.3 values ( A and C ) or cytokine levels ( B and D ) for each treatment group: ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05. Error bars depict SD.

Article Snippet: Renca tumor cells (ATCC, #CRL-2947, RRID:CVCL_2174; purchased in 2004) were cultured in RPMI 1640 medium (ATCC) with 10% heat-inactivated FBS, MEM nonessential amino acids (0.1 mmol/L), sodium pyruvate (1 mmol/L), and L-glutamine (2 mmol/L) and implanted subcutaneously (2 × 10 6 cells in 200 μL 25% Matrigel in RPMI 1640) into Balb/c female mice (RRID:IMSR_ENV:HSD-047).

Techniques: Clinical Proteomics, In Vivo

Journal: Molecular Cancer Therapeutics

Article Title: Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models

doi: 10.1158/1535-7163.MCT-25-0108

Figure Lengend Snippet: Tumor-targeted ncSTING ADCs with a WT Fc backbone drive enhanced antitumor activity in some, but not all, tumor models. Mean tumor volume over time of ( A ) human CD228-LL2 tumor–bearing C57BL/6 mice, ( B ) murine B7-H4-EMT6 tumor–bearing C57BL/6 mice, ( C ) murine B7-H4-Renca tumor–bearing Balb/c mice, ( D ) murine IB6-CT26 tumor–bearing Balb/c mice, ( E ) MC38 tumor–bearing C57BL/6 mice, and ( F ) MC38 tumor–bearing C57BL/6 WT and STING-deficient mice following treatment with the three weekly intraperitoneal doses (arrows) or a single dose (denoted by “x1”) of the indicated ADCs. Data in each panel represent a single in vivo experiment. Following a one-way ANOVA test, a Tukey post hoc multiple comparisons test was used to compare AUC.3 values for each treatment group: ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05. Error bars depict SD.

Article Snippet: Renca tumor cells (ATCC, #CRL-2947, RRID:CVCL_2174; purchased in 2004) were cultured in RPMI 1640 medium (ATCC) with 10% heat-inactivated FBS, MEM nonessential amino acids (0.1 mmol/L), sodium pyruvate (1 mmol/L), and L-glutamine (2 mmol/L) and implanted subcutaneously (2 × 10 6 cells in 200 μL 25% Matrigel in RPMI 1640) into Balb/c female mice (RRID:IMSR_ENV:HSD-047).

Techniques: Activity Assay, In Vivo